Key Metrics of TG Therapeutics
Revenue$234M▲ 8,290.0% YoYFY 2023
Operating income$20.6M▲ 109.5% YoY
Net profit$12.7M▲ 106.4% YoY
Shareholders' equity$161M
Market cap$8.8BTGTX · $57.40
About TG Therapeutics
Company details
- Website
- tgtherapeutics.com
- Listed
- Nasdaq: TGTX
Company summary
Legal nameTG Therapeutics Inc.
TickerTGTX
ExchangeNasdaq
CountryUnited States
SEC CIK0001001316
Listed since—
IndustryBiotechnology: Pharmaceutical Preparations
SectorOther Industries · Discovered Companies
Websitehttp://tgtherapeutics.com
US market & SEC filings
TGTX · Nasdaq · SEC CIK 0001001316
Last price · 29 Oct 2026
$57.40
+1.70%
Market cap$8.8B
P/E637.8On FY 2023 diluted EPS
Volume933,815
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited States
TGTX share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeNew York City
GSTIN—
Email—
Websitehttp://tgtherapeutics.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.